Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-leukemia antigen-specific T cells
- Development stage
- Unknown
- Lead developer
- Marker Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Multi-leukemia antigen-specific T cells (mLSTs) are an investigational adoptive cell-based immunotherapy designed to treat myeloid malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), particularly in the post-allogeneic hematopoietic stem cell transplant (HCT) setting. This biologic therapy consists of donor-derived cytotoxic T lymphocytes (CTLs) that are expanded ex vivo using peptide libraries to recognize five specific tumor-associated antigens (TAAs): proteinase 3 (Pr3), Wilms tumor gene 1 (WT1), human neutrophil elastase (NE), preferentially expressed antigen in melanoma (PRAME), and melanoma-associated antigen A3 (MAGE-A3). By targeting multiple antigens simultaneously, mLSTs aim to provide broad anti-leukemic activity, overcome tumor heterogeneity, and minimize the risk of immune escape. The therapy is intended to enhance the graft-versus-leukemia (GvL) effect without inducing significant graft-versus-host disease (GvHD), cytokine release syndrome, or neurotoxicity.
- Other names
- multi-antigen-specific T cellsleukemia-specific T cellsmulti-TAA-specific T cells
02
Targets
PRTN3 (Proteinase 3)WT1 (Wilms tumor protein)PRAME (Preferentially expressed antigen in melanoma)MAGEA3 (Melanoma-associated antigen 3)ELANE (Human Neutrophil Elastase)
Beyond the preview
Go deeper on multi-leukemia antigen-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-leukemia antigen-specific T cells.